The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2016

Filed:

Jul. 05, 2013
Applicant:

Ucb Biopharma Sprl, Brussels, BE;

Inventors:

Jonathan Mark Bentley, Abingdon, GB;

Daniel Christopher Brookings, Slough, GB;

Julien Alistair Brown, Slough, GB;

Thomas Paul Cain, Abingdon, GB;

Praful Tulshi Chovatia, Abingdon, GB;

Anne Marie Foley, Slough, GB;

Ellen Olivia Gallimore, Slough, GB;

Laura Jane Gleave, Abingdon, GB;

Alexander Heifetz, Abingdon, GB;

Helen Tracey Horsley, Slough, GB;

Martin Clive Hutchings, Slough, GB;

Victoria Elizabeth Jackson, Slough, GB;

James Andrew Johnson, Slough, GB;

Craig Johnstone, Abingdon, GB;

Boris Kroeplien, Slough, GB;

Fabien Claude Lecomte, Slough, GB;

Deborah Leigh, Abingdon, GB;

Martin Alexander Lowe, Slough, GB;

James Madden, Abingdon, GB;

John Robert Porter, Slough, GB;

Joanna Rachel Quincey, Slough, GB;

Laura Claire Reed, Abingdon, GB;

James Thomas Reuberson, Slough, GB;

Anthony John Richardson, Abingdon, GB;

Sarah Emily Richardson, Abingdon, GB;

Matthew Duncan Selby, Slough, GB;

Michael Alan Shaw, Slough, GB;

Zhaoning Zhu, Slough, GB;

Assignee:

UCB Biopharma SPRL, Brussels, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 491/02 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/5513 (2006.01); A61K 31/554 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/554 (2013.01); A61K 31/5513 (2013.01); C07D 491/107 (2013.01); C07D 519/00 (2013.01);
Abstract

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.


Find Patent Forward Citations

Loading…